Share on LinkedInShare on LinkedIn

ARTICLE · 22 JUNE 2017

Sandoz v. Amgen Supreme Court Decision

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Below, a divided Federal Circuit panel held that: (1) a biosimilar applicant is not required to provide its application and manufacturing information to the Reference Product Sponsor (RPS)

United StatesIntellectual Property

On June 12, 2017, the U.S. Supreme Court issued a unanimous decision in Sandoz Inc. v. Amgen Inc., Nos. 15-1039, 15-1195,1  interpreting two provisions of the Biologics Price Competition and Innovation Act (BPCIA).2 Below, a divided Federal Circuit panel held that: (1) a biosimilar applicant is not required to provide its application and manufacturing information to the Reference Product Sponsor (RPS), and the BPCIA contains the "exclusive" remedies for any such failure to comply with this disclosure provision; and (2) a biosimilar applicant may only provide its 180-day notice of commercial marketing after the FDA has licensed the biosimilar.3 On appeal, the Court vacated in part and reversed in part, remanding the cases back to the Federal Circuit for further proceedings.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from